Nxera Pharma Co., Ltd.

As of June 30, 2026, Nxera Pharma Co., Ltd. carries a market capitalization of 90.46B, placing it among publicly traded companies globally. Its enterprise value stands at 127.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nxera Pharma Co., Ltd.'s next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Nxera Pharma Co., Ltd. has 91.38M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Nxera Pharma Co., Ltd. maintains a current ratio of 2.66, meaning it holds 2.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Nxera Pharma Co., Ltd.'s stock has gained approximately 33.95% over the past 52 weeks. The 50-day moving average sits at 1,177.48, while the 200-day moving average is 999.98.

As of June 30, 2026, Nxera Pharma Co., Ltd. holds 17.75B in cash and equivalents against 54.41B in total debt, resulting in a net debt position of 33.28B. Total book value stands at 64.80B, with working capital of 25.07B providing operational flexibility.

Nxera Pharma Co., Ltd.'s most recent stock split took place on June 27, 2018 with a 1:4 split ratio.